Pipeline

S*BIO has identified SB1317, a kinase inhibitor with a unique kinase inhibitory spectrum and excellent pharmaceutical properties. It is potent inhibitor of Flt-3, JAK2 as well as CDKs. In January 2009, S*BIO announced it had granted a worldwide exclusive license to Tragara Pharmaceuticals Inc. to develop and commercialize SB1317. In partnership with Tragara Pharmaceuticals Inc., this unique spectrum will be exploited in the clinic in patients with advanced hematological malignancies as well as solid tumors.

Cyclin-dependent kinases (CDKs) are serine-threonine kinases that play important roles in cell cycle control, transcription and initiation. Aberrations in the cell cycle CDKs and their cyclin partners have been observed in various tumour types, including those of the breast, colon, liver and brain, making CDKs an attractive target for cancer therapy.

FLT3 belongs to the family of Class III receptor tyrosine kinases (RTK) that play an important role in the maintenance, growth and development of hematopoietic and non-hematopoietic cells. Mutations of these RTKs are known to be involved in the pathophysiology of diverse human cancers from both solid and hematological origins. FLT3 mutations are the most frequent genetic alterations reported in acute myeloid leukemia (AML) and are strongly associated with a poor prognosis.

Currently, several FLT3 inhibitors are in different stages of clinical testing for AML, but long-term sustained clinical response has not been observed. It is believed that this is a reflection of the need to target multiple components in the oncogenic pathway.

Back to top

Copyright © 2002-2011 S*BIO Pte Ltd. All rights reserved.